Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Shares Outstanding (Weighted Average) (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Shares Outstanding (Weighted Average) readings, the most recent being $13.4 million for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.29% to $13.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Sep 2025, up 3.29% year-over-year, with the annual reading at $13.0 million for FY2024, 64411.67% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $13.4 million in Q3 2025 for Greenwich LifeSciences, up from $13.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $13.4 million in Q3 2025 and bottomed at $20174.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $11.6 million, with a median of $12.9 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 99.84% in 2023 before it surged 64411.67% in 2024.
  • Greenwich LifeSciences' Shares Outstanding (Weighted Average) stood at $20174.0 in 2021, then soared by 63912.33% to $12.9 million in 2022, then tumbled by 99.84% to $20174.0 in 2023, then surged by 64411.67% to $13.0 million in 2024, then rose by 2.93% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Shares Outstanding (Weighted Average) are $13.4 million (Q3 2025), $13.3 million (Q2 2025), and $13.2 million (Q1 2025).